Leroy Jef L, Brander Rebecca L, Frongillo Edward A, Larson Leila M, Ruel Marie T, Avula Rasmi
International Food Policy Research Institute, Washington, DC, United States.
International Food Policy Research Institute, Washington, DC, United States.
Adv Nutr. 2025 Mar;16(3):100367. doi: 10.1016/j.advnut.2025.100367. Epub 2025 Jan 11.
Growth monitoring and promotion (GMP), the process of periodic anthropometric measurements to assess the adequacy of individual child growth, is implemented across low-income and middle-income countries. The epidemiologic foundations of GMP (i.e., that GMP can accurately diagnose or screen for inadequate growth) have never been critically reviewed. We first assessed growth patterns of individual healthy children. Using longitudinal data from low-income, middle-income, and high-income countries, we evaluated whether commonly used GMP criteria can be used for diagnosis and screening; i.e., whether they accurately identify current, or predict subsequent, inadequate growth in individual children. The growth of individual healthy children does not track along a specific growth curve, which challenges the notion that growth measurements alone can be used to distinguish between healthy and inadequate growth. We demonstrated that GMP criteria do not provide meaningful diagnostic information and that GMP is not a meaningful screening activity: commonly used GMP criteria are inaccurate predictors of (inadequate) growth later in childhood, and collecting individual children's weight and height does not help to identify who needs support or who will benefit. Our results do not undermine the importance of dedicated programs to diagnose wasting in individual children nor do they challenge the need for well-child care to support parents and to ensure children's optimal nutrition, health, and development. Our findings, however, highlight the need to carefully reconsider the current design of GMP in low-income and middle-income countries.
生长监测与促进(GMP),即通过定期进行人体测量来评估个体儿童生长是否充足的过程,在低收入和中等收入国家广泛实施。然而,GMP的流行病学基础(即GMP能够准确诊断或筛查生长不足)从未得到过严格审查。我们首先评估了个体健康儿童的生长模式。利用来自低收入、中等收入和高收入国家的纵向数据,我们评估了常用的GMP标准是否可用于诊断和筛查;也就是说,它们能否准确识别个体儿童当前的生长不足,或预测其随后的生长不足。个体健康儿童的生长并非沿着特定的生长曲线发展,这对仅通过生长测量就能区分健康生长和生长不足的观点提出了挑战。我们证明,GMP标准无法提供有意义的诊断信息,而且GMP并非一项有意义的筛查活动:常用的GMP标准并不能准确预测儿童后期的(生长不足)情况,收集个体儿童的体重和身高无助于确定谁需要支持或谁将从中受益。我们的研究结果并未削弱针对个体儿童诊断消瘦的专门项目的重要性,也没有质疑提供儿童健康护理以支持家长并确保儿童获得最佳营养、健康和发展的必要性。然而,我们的研究结果凸显了仔细重新审视低收入和中等收入国家当前GMP设计的必要性。